LadRx (LADX) Stock Overview
A biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
LADX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
LadRx Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.12 |
| 52 Week High | US$2.40 |
| 52 Week Low | US$0.0001 |
| Beta | 0.51 |
| 1 Month Change | -7.69% |
| 3 Month Change | -91.72% |
| 1 Year Change | -93.51% |
| 3 Year Change | -98.40% |
| 5 Year Change | -99.93% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| LADX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.7% | 1.3% |
| 1Y | -93.5% | 27.1% | 15.8% |
Return vs Industry: LADX underperformed the US Biotechs industry which returned 26.7% over the past year.
Return vs Market: LADX underperformed the US Market which returned 14.6% over the past year.
Price Volatility
| LADX volatility | |
|---|---|
| LADX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LADX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine LADX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 2 | n/a | www.ladrxcorp.com |
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer.
LadRx Corporation Fundamentals Summary
| LADX fundamental statistics | |
|---|---|
| Market cap | US$59.41k |
| Earnings (TTM) | -US$2.50m |
| Revenue (TTM) | n/a |
Is LADX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LADX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.50m |
| Earnings | -US$2.50m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.04 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LADX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/25 02:51 |
| End of Day Share Price | 2025/12/18 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LadRx Corporation is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ashok Kumar | Aegis Capital Corporation |
| Morris Ajzenman | Griffin Securities |
| Andrew Fein | H.C. Wainwright & Co. |